Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
bluebird bio的股票在公司宣佈其加入CMMI電芯和基因療法獲取模式，並將提供基於結果的協議以擴大對LYFGENIA基因療法的醫保獲取之後，交易價格上漲。
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
bluebird bio的股價上漲，因爲該公司宣佈加入CMMI電芯和基因療法獲取模型，並將提供基於結果的協議，以擴大LYFGENIA基因療法對鐮狀細胞病的醫療保險覆蓋範圍。
資訊熱榜
更新時間